3
Announcements
Trials
Browse
Landscape
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
2
Sponsor
Cancer Type
Other hematologic neoplasm
5
Myeloid
4
Lymphoid
4
Plasma cell
2
Other solid neoplasm
2
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
77
Injections
67
Carboplatin
38
Nivolumab
31
Pemetrexed
29
Cisplatin
29
Cyclophosphamide
25
Specimen Handling
24
Interviews as Topic
24
tislelizumab
20
atezolizumab
20
Bevacizumab
20
Paclitaxel
19
fludarabine
16
Standard of Care
16
Practice Guidelines as Topic
16
Docetaxel
16
Ipilimumab
15
toripalimab
14
Educational Status
14
Cetuximab
14
Fluorouracil
13
Oxaliplatin
12
Etoposide
12
olaparib
11
durvalumab
11
Methods
11
Gemcitabine
11
Early Intervention, Educational
11
Drug Therapy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Other solid neoplasm
×
1 year
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled
NCT07137312
2025-12-23
Ex Vivo Expansion (ACT-X)
Mayo Clinic
Recruiting
24 enrolled